|
DE60335359D1
(de)
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
PL1633724T3
(pl)
*
|
2003-03-12 |
2011-10-31 |
Kudos Pharm Ltd |
Pochodne ftalazynonu
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
GB0317466D0
(en)
*
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
US7456180B2
(en)
|
2003-07-30 |
2008-11-25 |
Xenon Pharmaceuticals Inc. |
Piperazine derivatives and their use as therapeutic agents
|
|
AR046078A1
(es)
|
2003-08-06 |
2005-11-23 |
Senomyx Inc |
Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.
|
|
GB0324159D0
(en)
|
2003-10-15 |
2003-11-19 |
Glaxo Group Ltd |
Novel compounds
|
|
PL2305221T3
(pl)
*
|
2003-12-01 |
2015-11-30 |
Kudos Pharm Ltd |
Inhibitory naprawy uszkodzeń DNA w leczeniu raka
|
|
GB0419072D0
(en)
|
2004-08-26 |
2004-09-29 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
JP2008510783A
(ja)
*
|
2004-08-26 |
2008-04-10 |
クドス ファーマシューティカルズ リミテッド |
４−ヘテロアリールメチル置換フタラジノン誘導体
|
|
EP1645556A1
(en)
*
|
2004-10-07 |
2006-04-12 |
Boehringer Ingelheim International GmbH |
Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
|
|
JP4734346B2
(ja)
*
|
2005-02-04 |
2011-07-27 |
セノミックス インコーポレイテッド |
連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
TW200715993A
(en)
|
2005-06-15 |
2007-05-01 |
Senomyx Inc |
Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
|
|
US7816351B2
(en)
*
|
2005-09-23 |
2010-10-19 |
Equispharm Co., Ltd |
5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
|
|
GB0521373D0
(en)
|
2005-10-20 |
2005-11-30 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
|
ES2640453T3
(es)
|
2006-04-21 |
2017-11-03 |
Senomyx, Inc. |
Procesos para preparar composiciones saborizantes sólidas
|
|
GB0610680D0
(en)
|
2006-05-31 |
2006-07-12 |
Istituto Di Ricerche D Biolog |
Therapeutic compounds
|
|
WO2007138355A1
(en)
|
2006-05-31 |
2007-12-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
|
|
US20090281086A1
(en)
*
|
2006-06-15 |
2009-11-12 |
Kudos Pharmaceuticals Limited |
2 -oxyheteroarylamide derivatives as parp inhibitors
|
|
WO2008020180A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Kudos Pharmaceuticals Limited |
Methods of increasing the sensitivity of cancer cells to dna damage
|
|
AU2013201880B2
(en)
*
|
2006-10-17 |
2015-06-25 |
Kudos Pharmaceuticals Limited |
Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
|
|
UY30639A1
(es)
*
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
PE20081229A1
(es)
*
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
ES2548353T3
(es)
|
2006-12-28 |
2015-10-15 |
Abbvie Inc. |
Inhibidores de poli(ADP-ribosa)polimerasa
|
|
US20100249112A1
(en)
*
|
2007-05-25 |
2010-09-30 |
Astrazeneca R&D |
Combination of chk and parp inhibitors for the treatment of cancers
|
|
JP5603770B2
(ja)
|
2007-05-31 |
2014-10-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｃｒ２受容体拮抗薬およびその使用
|
|
US20090023727A1
(en)
*
|
2007-07-05 |
2009-01-22 |
Muhammad Hashim Javaid |
Phthalazinone derivatives
|
|
GB0716532D0
(en)
*
|
2007-08-24 |
2007-10-03 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
ES2504690T3
(es)
*
|
2007-10-03 |
2014-10-08 |
Eisai Inc. |
Compuestos inhibidores de PARP, composiciones y métodos de uso
|
|
CA2702429A1
(en)
*
|
2007-10-17 |
2009-04-23 |
Kudos Pharmaceuticals Limited |
Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
|
|
EP2220073B1
(en)
*
|
2007-11-15 |
2014-09-03 |
MSD Italia S.r.l. |
Pyridazinone derivatives as parp inhibitors
|
|
CL2008003553A1
(es)
*
|
2007-12-05 |
2009-11-27 |
Grindeks Jsc |
Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
|
|
BRPI0820701A2
(pt)
|
2007-12-11 |
2015-06-16 |
Cytopathfinder Inc |
Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
|
|
UY31603A1
(es)
*
|
2008-01-23 |
2009-08-31 |
|
Derivados de ftalazinona
|
|
CN104478875B
(zh)
|
2008-08-06 |
2017-04-12 |
麦迪韦逊科技有限公司 |
聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
|
|
CA2737400C
(en)
|
2008-10-07 |
2016-11-22 |
Astrazeneca Uk Limited |
Pharmaceutical formulation 514
|
|
CN102256963B
(zh)
|
2008-12-19 |
2014-06-11 |
贝林格尔.英格海姆国际有限公司 |
作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
|
|
US20110015393A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Astrazeneca Ab |
Phthalazinone compound
|
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
|
WO2011058367A2
(en)
|
2009-11-13 |
2011-05-19 |
Astrazeneca Ab |
Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
|
|
EP2322658A1
(en)
|
2009-11-13 |
2011-05-18 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of breast cancer aggressiveness and genetic instability
|
|
ES2674275T3
(es)
|
2009-12-17 |
2018-06-28 |
Centrexion Therapeutics Corporation |
Antagonistas del receptor CCR2 y usos de los mismos
|
|
EP2531033A4
(en)
|
2010-02-03 |
2013-07-31 |
Biomarin Pharm Inc |
POLY (ADP-RIBOSE) POLYMERASE (PARP) DIHYDROPYRIDOPHTHALAZINE HEMMER FOR USE IN THE TREATMENT OF PTEN-LACK ASSOCIATED DISEASES
|
|
KR101826652B1
(ko)
|
2010-02-08 |
2018-02-07 |
메디베이션 테크놀로지즈, 인크. |
디히드로피리도프탈라지논 유도체의 합성 방법
|
|
JP5646736B2
(ja)
|
2010-05-12 |
2014-12-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
|
|
WO2011141474A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
WO2011144501A1
(en)
|
2010-05-17 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 antagonists and uses thereof
|
|
WO2011147772A1
(en)
|
2010-05-25 |
2011-12-01 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists
|
|
US8962656B2
(en)
|
2010-06-01 |
2015-02-24 |
Boehringer Ingelheim International Gmbh |
CCR2 antagonists
|
|
JP2013532683A
(ja)
*
|
2010-07-27 |
2013-08-19 |
カディラ ヘルスケア リミティド |
ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
|
|
CN102372716A
(zh)
*
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
KR20190120458A
(ko)
*
|
2010-10-21 |
2019-10-23 |
메디베이션 테크놀로지즈 엘엘씨 |
결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
|
|
JP5699223B2
(ja)
*
|
2010-12-02 |
2015-04-08 |
シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド |
複素環誘導体、その合成法および医療用途
|
|
CA2829123C
(en)
*
|
2011-03-14 |
2016-04-12 |
Eternity Bioscience Inc. |
Quinazolinediones and their use
|
|
EP2709618A4
(en)
*
|
2011-05-10 |
2014-11-05 |
UNIVERSITé LAVAL |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
|
|
EP2710142B1
(en)
|
2011-05-18 |
2017-04-26 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of cancer aggressiveness and genetic instability
|
|
TWI577693B
(zh)
*
|
2011-05-31 |
2017-04-11 |
江蘇康緣藥業股份有限公司 |
聚（ａｄｐ-核糖）聚合酶之三環抑制劑
|
|
EP2731941B1
(en)
|
2011-07-15 |
2019-05-08 |
Boehringer Ingelheim International GmbH |
Novel and selective ccr2 antagonists
|
|
JP6270719B2
(ja)
|
2011-07-22 |
2018-01-31 |
パシレックス・ファーマシューティカルズ・インコーポレイテッド |
合成致死性および癌の治療
|
|
CN103130723B
(zh)
*
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
EP2800821B1
(en)
|
2012-01-05 |
2016-11-16 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of lung cancer aggressiveness
|
|
CN102964354B
(zh)
*
|
2012-11-16 |
2014-08-13 |
江苏先声药业有限公司 |
一类噻吩并咪唑衍生物及其应用
|
|
HUE030613T2
(en)
|
2012-12-31 |
2017-05-29 |
Cadila Healthcare Ltd |
Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
|
|
EP2968323A4
(en)
|
2013-03-13 |
2016-12-14 |
Flatley Discovery Lab |
PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
CA2904393A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
PL3027598T3
(pl)
*
|
2013-07-31 |
2017-09-29 |
Merck Patent Gmbh |
Pochodne oksochinazolinylo-butanoamidowe
|
|
KR102249564B1
(ko)
*
|
2013-08-07 |
2021-05-07 |
메르크 파텐트 게엠베하 |
피페리딘 우레아 유도체
|
|
KR101670126B1
(ko)
|
2013-09-13 |
2016-10-27 |
일동제약(주) |
신규 프탈라지논 유도체 및 그 제조방법
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
CN105985294B
(zh)
*
|
2015-02-11 |
2020-12-25 |
四川科伦药物研究院有限公司 |
一种奥拉帕尼的制备方法
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
CN106146492A
(zh)
*
|
2015-04-17 |
2016-11-23 |
上海汇伦生命科技有限公司 |
杂环并咪唑类化合物、其药物组合物及其制备方法和用途
|
|
AU2016258192B2
(en)
|
2015-05-06 |
2021-07-29 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
EP3298005B1
(en)
|
2015-05-21 |
2024-01-24 |
The Regents of The University of California |
Anti-cancer compounds
|
|
PT3317270T
(pt)
|
2015-07-02 |
2020-08-24 |
Centrexion Therapeutics Corp |
(4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona
|
|
JP7539760B2
(ja)
|
2015-07-17 |
2024-08-26 |
パシレックス・ファーマシューティカルズ・インコーポレイテッド |
Ｎｍｔ２の後成的なサイレンシング
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
AU2016296905B2
(en)
|
2015-07-23 |
2018-07-05 |
Centre National De La Recherche Scientifique |
Use of a combination of Dbait molecule and parp inhibitors to treat cancer
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
CN106554316B
(zh)
*
|
2015-09-28 |
2019-03-08 |
上海医药集团股份有限公司 |
一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
JP7017509B2
(ja)
|
2015-11-20 |
2022-02-08 |
センワ バイオサイエンシズ インコーポレイテッド |
がんを治療するための四環式キノロン類似体の併用療法
|
|
CZ201682A3
(cs)
|
2016-02-15 |
2017-08-23 |
Zentiva, K.S. |
Solvatované krystalické formy olaparibu, jejich příprava a použití
|
|
WO2017191562A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Alembic Pharmaceuticals Limited |
Process for the preparation of olaparib and polymorphs thereof
|
|
WO2017223516A1
(en)
|
2016-06-24 |
2017-12-28 |
The Regents Of The University Of California |
Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
|
|
CZ2016391A3
(cs)
|
2016-06-29 |
2018-01-10 |
Zentiva, K.S. |
Farmaceutická formulace olaparibu
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018038680A1
(en)
*
|
2016-08-24 |
2018-03-01 |
Scinopharm Taiwan, Ltd. |
Processes for preparing olaparib
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
CN107955001A
(zh)
*
|
2016-10-14 |
2018-04-24 |
上海汇伦生命科技有限公司 |
抗肿瘤杂环并咪唑类化合物的药用盐
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
EP3612526A2
(en)
|
2017-04-20 |
2020-02-26 |
The Regents of the University of California |
K-ras modulators
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
CA3031777A1
(en)
|
2018-01-31 |
2019-07-31 |
Apotex Inc. |
Crystalline form of olaparib
|
|
CN112334133A
(zh)
|
2018-02-15 |
2021-02-05 |
生华生物科技股份有限公司 |
喹诺酮类似物及其盐、组合物及其使用方法
|
|
EP3758695A4
(en)
*
|
2018-02-28 |
2021-10-06 |
The Trustees Of The University Of Pennsylvania |
POLY (AD-RIBOSE) -POLYMERASE 1 DEPENDENT CYTOTOXIC AGENTS WITH LOW AFFINITY
|
|
CA3092779A1
(en)
|
2018-03-13 |
2019-09-19 |
Onxeo |
A dbait molecule against acquired resistance in the treatment of cancer
|
|
GB201804924D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Univ Oxford Innovation Ltd |
Radiolabelled compound
|
|
WO2019196812A1
(zh)
*
|
2018-04-09 |
2019-10-17 |
上海科技大学 |
蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
|
|
CA3099155A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN108558773A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种奥拉帕尼药物中间体的制备方法
|
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
CN111606883B
(zh)
|
2019-02-25 |
2023-05-09 |
上海科技大学 |
基于戊二酰亚胺骨架的含硫化合物及其应用
|
|
CA3138197A1
(en)
|
2019-05-14 |
2020-11-19 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
SI3999506T1
(sl)
|
2019-07-19 |
2025-06-30 |
Astrazeneca Ab |
Zaviralci PARP1
|
|
WO2021023233A1
(zh)
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN115038439B
(zh)
*
|
2020-01-07 |
2026-04-21 |
上海华禹生物科技有限公司 |
使用chk抑制剂的癌症联合疗法
|
|
KR20220124739A
(ko)
|
2020-01-09 |
2022-09-14 |
아스트라제네카 아베 |
암의 치료를 위한 병용 요법
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CA3169303A1
(en)
*
|
2020-02-24 |
2021-09-02 |
Xiaokun SHEN |
Application of poly adp-ribose polymerase inhibitors in corona virus resistance
|
|
AU2020444056A1
(en)
|
2020-04-21 |
2022-11-17 |
Idience Co., Ltd. |
Crystalline forms of phthalazinone compound
|
|
JP7626783B2
(ja)
|
2020-04-21 |
2025-02-07 |
アイディーエンス カンパニー リミテッド |
フタラジノン誘導体及びその中間体を調製するプロセス
|
|
US20230234938A1
(en)
|
2020-04-28 |
2023-07-27 |
Rhizen Pharmaceuticals Ag |
Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
|
|
CN111592522B
(zh)
*
|
2020-06-17 |
2022-09-09 |
郑州大学 |
一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
|
|
US11795158B2
(en)
|
2020-06-25 |
2023-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2022058785A1
(en)
|
2020-09-16 |
2022-03-24 |
Nuformix Technologies Limited |
Olaparib oxalic acid cocrystals and their pharmaceutical use
|
|
JP2023545096A
(ja)
|
2020-10-09 |
2023-10-26 |
アストラゼネカ ユーケー リミテッド |
抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ
|
|
US12059419B2
(en)
|
2020-10-16 |
2024-08-13 |
Idience Co., Ltd. |
Pharmaceutical composition comprising phthalazinone derivatives
|
|
WO2022090938A1
(en)
|
2020-10-31 |
2022-05-05 |
Rhizen Pharmaceuticals Ag |
Phthalazinone derivatives useful as parp inhibitors
|
|
CN112500379B
(zh)
*
|
2020-12-23 |
2024-01-23 |
南京方生和医药科技有限公司 |
一种奥拉帕利中间体及奥拉帕利的制备方法
|
|
MX2023011241A
(es)
|
2021-03-23 |
2023-10-03 |
Nuvation Bio Inc |
Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
|
|
CN113024516B
(zh)
*
|
2021-03-29 |
2022-05-17 |
中国药科大学 |
双靶点parp/ezh2抑制剂、制备方法及用途
|
|
CA3214298A1
(en)
|
2021-04-08 |
2022-10-13 |
Swaroop Kumar Venkata Satya VAKKALANKA |
Inhibitors of poly(adp-ribose) polymerase
|
|
JP2024516024A
(ja)
|
2021-05-03 |
2024-04-11 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
MA63136A1
(fr)
|
2021-05-18 |
2024-06-28 |
Onconic Therapeutics Inc. |
Agent thérapeutique contre le cancer résistant à un inhibiteur de parp
|
|
CA3220751A1
(en)
*
|
2021-06-02 |
2022-12-08 |
Astrazeneca Ab |
Methods of treating breast cancer
|
|
EP4384501A4
(en)
|
2021-08-09 |
2025-01-22 |
Glenmark Life Sciences Limited |
Process for the preparation of olaparib, and crystalline form thereof
|
|
KR102645122B1
(ko)
*
|
2021-08-25 |
2024-03-07 |
주식회사 보령 |
올라파립의 제조방법
|
|
CN115806526B
(zh)
*
|
2021-09-15 |
2025-05-06 |
上海博邦医药科技有限公司 |
一种奥拉帕尼中间体的制备方法
|
|
CN118696032A
(zh)
|
2021-11-10 |
2024-09-24 |
努福米克斯技术有限公司 |
奥拉帕尼羟基苯甲酸共晶体及其药物用途
|
|
AU2022392822A1
(en)
|
2021-11-18 |
2024-05-02 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
EP4452256B1
(en)
|
2021-12-21 |
2025-12-10 |
Astrazeneca AB |
Methods of treating brain tumours and neuroblastomas
|
|
KR102776660B1
(ko)
*
|
2022-01-25 |
2025-03-04 |
재단법인 한국파스퇴르연구소 |
벤조다이옥세인 유도체 화합물 및 이의 의약 용도
|
|
CN118829430A
(zh)
|
2022-02-15 |
2024-10-22 |
阿斯利康(瑞典)有限公司 |
治疗前列腺癌的方法
|
|
KR20250165438A
(ko)
|
2023-03-31 |
2025-11-25 |
아스트라제네카 아베 |
Azd5305의 투여 레지먼
|
|
CN119055777A
(zh)
|
2023-05-31 |
2024-12-03 |
阿斯利康(瑞典)有限公司 |
用于治疗卵巢癌的方法、组合物和组合
|
|
CN121398822A
(zh)
|
2023-06-21 |
2026-01-23 |
四方生物科学有限公司 |
用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
|
|
CN119488588A
(zh)
|
2023-08-17 |
2025-02-21 |
阿斯利康(瑞典)有限公司 |
用于治疗子宫内膜癌的方法、组合物和组合
|
|
TW202535479A
(zh)
|
2023-12-05 |
2025-09-16 |
英商阿斯特捷利康英國股份有限公司 |
抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
|
|
TW202545525A
(zh)
|
2024-01-19 |
2025-12-01 |
瑞典商阿斯特捷利康公司 |
包含ａｚｄ５３０５之藥物組成物
|
|
WO2026013152A1
(en)
|
2024-07-09 |
2026-01-15 |
Stada Arzneimittel Ag |
Pharmaceutical composition comprising olaparib
|
|
EP4682140A1
(en)
|
2024-07-17 |
2026-01-21 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Improved process for the preparation of olaparib
|